ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION

• US 20090326040A1
• Filed: 08/10/2005
• Published: 12/31/2009
• Est. Priority Date: 08/10/2004
• Status: Abandoned Application

• Current Assignee: Kastle Therapeutics, LLC.
• Original Assignee: ISIS Pharmaceuticals Incorporated (Ionis Pharmaceuticals, Inc.)
• Inventors: Crooke, Rosanne M., Geary, Richard S., Yu, Zhengrong
• Application Number:
  US11/573,537
• Publication Number:
  US 20090326040A1
• Time in Patent Office: Days
• US Class Current: 514/44.00A
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/1137 against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/3341 5-Methylcytosine
• CPC Class Codes: C12N 2310/341 Gapmers, i.e. of the type ===---===
• CPC Class Codes: C12N 2310/346 having a combination of backbone and sugar modifications
• CPC Class Codes: C12N 2310/3525 MOE, methoxyethoxy

Abstract

Methods for the rapid and long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated apolipoprotein B are provided.

Claims

1-39. -39. (canceled)

40. A method of reducing serum LDL-cholesterol in a human subject comprising administering to said human subject an oligonucleotide 14 to 30 nucleobases in length, said oligonucleotide comprising the nucleobase sequence “

GCCTCAGTCTGCTTCGCACC”

(SEQ ID NO;

     2), wherein said oligonucleotide is administered during a loading period and a maintenance period.

42. The method of claim 40, wherein the loading period comprises administering the oligonucleotide to the human subject multiple times over a period of at least five days.

44. The method of claim 40, wherein the maintenance period comprises administering the oligonucleotide from once about every week to once about every month.

49. The method of claim 40, wherein a dose from about 0.1 mg/kg/day to about 5 mg/kg/day is administered.

51. The method of claim 40, wherein a dose is from about 50 mg per week to about 600 mg per week is administered.

56. The method of claim 40, wherein said oligonucleotide comprises ISIS 301012.

57. The method of claim 40, wherein said method results in a reduction in serum VLDL-cholesterol, serum triglycerides, serum lipoprotein(a) or any combination of VLDL-cholesterol, serum triglycerides and serum lipoprotein(a).

58. The method of claim 40, wherein said human subject exhibits at least one indication selected from the group consisting of:

an elevated serum total cholesterol level, an elevated serum LDL-cholesterol level, an elevated total cholesterol;

HDL ratio and an elevated LDL;

HDL ratio.

59. The method of claim 40, wherein said human subject has suffered from or suffers from homozygous familial hypercholesterolemia or heterozygous familial hypercholesterolemia.

60. The method of claim 40, wherein said human subject has suffered from, suffers from or is at an increased risk for nonfamilial hypercholesterolemia.

61. The method of claim 40, wherein the human subject has serum LDL-cholesterol levels above about 70 mg/dL prior to administering said oligonucleotide.

66. The method of claim 40 wherein administering said oligonucleotide reduces serum LDL cholesterol levels in the human subject to less than about 130 mg/dL.

41. (canceled)

43. (canceled)

45-48. -48. (canceled)

50. (canceled)

52-55. -55. (canceled)

62-65. -65. (canceled)

67. A method of reducing serum cholesterol levels in a human subject, comprising:

selecting a human subject previously unsuccessfully treated by a statin; and

administering to said human subject an oligonucleotide 14 to 30 nucleobases in length, said oligonucleotide comprising the nucleobase sequence “

GCCTCAGTCTGCTTCGCACC”

(SEQ ID NO;

     2).

68. The method of claim 67, wherein said serum cholesterol levels comprise serum LDL-cholesterol levels.

69. The method of claim 67, wherein the human subject is intolerant to a statin.

70. The method of claim 67, wherein the subject has experienced adverse effects resulting from treatment with said statin.

71. The method of claim 70, wherein the subject has experienced myopathy, fatigue, Central Nervous System (CNS) effects resulting from treatment with said statin or any combination of myopathy, fatigue, and CNS effects resulting from treatment with said statin.

72. The method of claim 67, wherein the human subject has insufficient LDL-receptor activity.

73. The method of claim 67, wherein said oligonucleotide comprises ISIS 301012.

74. A method of using an oligonucleotide 14 to 30 nucleobases in length comprising the nucleobase sequence “

GCCTCAGTCTGCTTCGCACC”

(SEQ ID NO;

     2) in a treatment for reducing serum LDL-cholesterol in a human subject, said method comprising informing said human subject that the administration of said oligonucleotide results in a plasma trough AUC of at least about 2 μ

g·

hr/mL.

75. The method of claim 74, wherein said human subject is informed that the administration of said oligonucleotide results in a plasma trough AUC in the range of about 2 μ

g·

hr/mL to about 20 μ

g·

hr/mL.

76. The method of claim 74, wherein said plasma trough AUC is achieved from about 3 to about 33 days subsequent to the administration of said dose of the oligonucleotide.

77. The method of claim 74, wherein informing said human subject comprises providing printed matter that advises that the administration of said oligonucleotide results in a plasma trough AUC of at least about 2 μ

g hr/mL.

78. The method of claim 77, wherein said printed matter is a label.

79. A method of using an oligonucleotide 14 to 30 nucleobases in length comprising the nucleobase sequence “

GCCTCAGTCTGCTTCGCACC”

(SEQ ID NO;

     2) in a treatment for reducing serum LDL-cholesterol in a human subject, said method comprising informing said human subject that the administration of said oligonucleotide results in a plasma trough concentration of at least about 5 ng/mL.

80. The method of claim 79, wherein said human subject is informed that the administration of said oligonucleotide results in a plasma trough concentration in the range of about 5 ng/mL to about 40 ng/mL.

81. The method of claim 79, wherein said plasma trough concentration is achieved about 7 days subsequent to the administration of said dose of the oligonucleotide.

82. The method of claim 79, wherein informing said human subject comprises providing printed matter that advises that the administration of said oligonucleotide results in a plasma trough concentration of at least about 5 ng/mL.

83. The method of claim 82, wherein said printed matter is a label.

84-216. -216. (canceled)